×
0 0 0 0 0 0.0756602426837973 0.0756602426837973 0.0756602426837973
Stock impact report

Concert Pharmaceuticals Selected for Late-Breaking Oral Presentation of CTP-543 Phase 2 Data in Alopecia Areata at 2019 AAD Annual Meeting

Concert Pharmaceuticals, Inc (CNCE)  More Company Research Source: Business Wire
Last concert pharmaceuticals, inc earnings: 5/2 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.concertpharma.com/investor-relations
PDF LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that interim clinical data from its CTP-543 Phase 2 trial in alopecia areata has been selected for an oral presentation at the Late-Breaking Research Program during the American Academy of Dermatology (AAD) Annual Meeting being held March 1 - 5, 2019 in Washington, D.C. The details of the presentation are as follows: Title: JAK Inhibitor CTP-543 Achieves Primary Endpoint in Phase 2 Trial in Alopecia Areata Date and Time: Saturday, March 2, 2019, 1:00 - 4:00 p.m. Session: S034: Late-Breaking Research: Clinical Trials Room: Ballroom A Abstract Number: 11291 About CTP-543 CTP-543 was discovered by applying Concert's deuterium chemistry technology to modify ruxolitinib, a drug which inhibits Janus kinases 1 [Read more]
Impact snapshot Event time: CNCE
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last price
VWAP
High:
Max up
High:
Low:
Max down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Opt-in for
CNCE alerts

from News Quantified
Opt-in for
CNCE alerts

from News Quantified